MT 5562
Alternative Names: MT-5562; MT-5562FLatest Information Update: 29 Dec 2023
At a glance
- Originator Mitsubishi Tanabe Pharma Corporation
- Class Antifibrotics; Skin disorder therapies
- Mechanism of Action ENPP2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Systemic scleroderma
Most Recent Events
- 10 Nov 2023 Pharmacodynamics and adverse events data from preclinical studies in Systemic scleroderma presented at the ACR Convergence 2023 (ACR-ARP-2023)
- 31 May 2023 Preclinical trials in Systemic scleroderma in Japan (PO), prior to May 2023
- 31 May 2023 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Systemic scleroderma presented at the 24th Annual Congress of the European League Against Rheumatism (EULAR-2023)